Conclusions & context. Emerging findings suggest disease areas with the potential for therapeutic benefit of 11β-HSD-1 use include metabolic syndromes. With diseases falling under this description, such as obesity, hypertension and diabetes, being known risk factors for dementia it may be a promising area for primary preventative strategies to focus on. We anticipate the completion of this review and publication of results in Spring 2019. Spring in the northern hemisphere is march, April, may.
Indications and collaborations, page-2
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $76.57M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $87.02K | 3.257M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 3262827 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 1154521 | 3 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |